New Peritoneal Cancer Pipeline (Oncology) Market Report for H1 2017 Published at ReportsnReports.com

PUNE, India, May 15, 2017 /PRNewswire-iReach/ -- Peritoneal Cancer Market Pipeline Assessment, H1 2017 report reviews products which include, product description, licensing and collaboration details and other developmental activities. The report latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology).

Content:

New pipeline report - Peritoneal Cancer Pipeline Market Review, H1 2017 is added to ReportsnReports.com store. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Browse the 114 Tables and 11 Figures, 83 Company Profiles, Spread across 959 Pages Report Available at http://www.reportsnreports.com/reports/992870-peritoneal-cancer-pipeline-review-h1-2017.html.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Key players of Peritoneal Cancer Pipeline are 3-V Biosciences Inc, AbbVie Inc, Adaptimmune Therapeutics Plc, Aduro BioTech Inc, Advenchen Laboratories LLC, Altor BioScience Corp, Amgen Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene Ltd, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corp, Celldex Therapeutics Inc, Celsion Corp, CerRx Inc, Clovis Oncology Inc, Critical Outcome Technologies Inc, Dr. Reddy's Laboratories Ltd, Eisai Co Ltd, Eli Lilly and Company, EpiThany Inc, Esperance Pharmaceuticals Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, Gene Techno Science Co Ltd, Genelux Corp, Genentech Inc, Genor BioPharma Co Ltd, Glycotope GmbH, Gradalis Inc, Hemispherx Biopharma Inc, ImmunoGen Inc, Immunovaccine Inc, Incyte Corp, Innate Pharma SA, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Lidds AB, Mabion SA, MabVax Therapeutics Holdings Inc, Mateon Therapeutics Inc, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, MolMed SpA, Mycenax Biotech Inc, NewLink Genetics Corp, Novartis AG, Novogen Ltd, Oasmia Pharmaceutical AB, OBI Pharma Inc, Oncobiologics Inc, Oncolix Inc, Oncolytics Biotech Inc, OncoMed Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd, Oxford BioMedica Plc, Pfizer Inc, Pharma Mar SA, Polaris Pharmaceuticals Inc, PsiOxus Therapeutics Ltd, Richter Gedeon Nyrt, Samyang Holdings Corp, Sanofi, Sanofi Pasteur SA, Sotio AS, Syndax Pharmaceuticals Inc, TapImmune Inc, Tyrogenex Inc, Vascular Biogenics Ltd, VentiRx Pharmaceuticals Inc, Verastem Inc.

Order a Copy of Report athttp://www.reportsnreports.com/purchase.aspx?name=992870 .

Peritoneal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Discount Available at http://www.reportsnreports.com/contacts/discount.aspx?name=992870 .

List of Figures

Number of Products under Development for Peritoneal Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Related New Reports:

Rhabdomyosarcoma - Pipeline Review, H1 2017

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017

Explore Other Reports on Pharmaceuticals Market at http://www.reportsnreports.com/market-research/pharmaceuticals/.

About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details at sales@reportsandreports.com ReportsnReports.com offers research studies on agriculture, energy and power, automotive, Semiconductor and Electronics, Manufacturing & Construction, chemicals, environment, medical devices, healthcare, food and beverages, water and much more.

Media Contact:Ritesh Tiwari, ReportsnReports, + 1 888 391 5441, sales@reportsandreports.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE ReportsnReports